Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.120 +0.050 (+1.23%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Where Will Recursion Pharmaceuticals Be in 5 Years? ↗

September 28, 2025

Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry?

Via The Motley Fool

Topics Animal Testing Artificial Intelligence

The Biotech Stock That's Too Risky for Most Investors ↗

September 28, 2025

It's unclear how long it's going to be before this company has a product to sell.

Via The Motley Fool

Topics Artificial Intelligence

10 Hidden-Gem AI Stocks to Buy Right Now ↗

September 27, 2025

From AI-powered insurance bots to drug discovery platforms, these overlooked stocks offer pure-play exposure to artificial intelligence without trillion-dollar valuations.

Via The Motley Fool

Topics Artificial Intelligence

Cramer's Friday Watchlist: AI Soars as Consumer Stumbles Amidst Economic Divide

September 26, 2025

As the trading week draws to a close on Friday, September 26, 2025, Jim Cramer, the influential host of CNBC's "Mad Money," has once again offered his discerning insights into the stock market's...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Jim Cramer Says This Financial Stock Is A 'Total Spec,' Likes Dutch Bros, ↗

September 26, 2025

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and then buying some of the stock in the $40s.

Via Benzinga

Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗

September 26, 2025

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Via The Motley Fool

Topics Artificial Intelligence

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Recursion Pharmaceuticals Earnings Preview ↗

August 04, 2025

Via Benzinga

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

July 29, 2025

Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST

From Recursion Pharmaceuticals

Via GlobeNewswire

Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery...

Via MarketMinute

Topics Animal Testing Artificial Intelligence Intellectual Property

Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch. ↗

September 15, 2025

Most of Nvidia's AI bets are riding on one stock.

Via The Motley Fool

Topics Artificial Intelligence

What Analysts Are Saying About Recursion Pharmaceuticals Stock ↗

September 11, 2025

Via Benzinga

When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts ↗

September 03, 2025

Nvidia's six-stock portfolio of publicly traded AI stocks was worth $4.3 billion at the end of the second quarter, and the company also owns stakes in many privately held AI start-ups.

Via The Motley Fool

Topics Artificial Intelligence ETFs Regulatory Compliance

3 AI Stocks Disrupting Trillion-Dollar Industries ↗

September 02, 2025

These three companies are using artificial intelligence (AI) to transform defense, pharmaceuticals, and banking.

Via The Motley Fool

Topics Artificial Intelligence Economy

If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today ↗

August 29, 2025

This AI company isn't yet living up to the hype.

Via The Motley Fool

Topics Artificial Intelligence

Recursion to Participate in Upcoming Investor Conferences

August 27, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell ↗

August 25, 2025

There might be better artificial intelligence (AI) stocks out there to buy.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode ↗

August 23, 2025

The artificial intelligence revolution is leaving no opportunity unaddressed.

Via The Motley Fool

Topics Artificial Intelligence

Why Recursion Pharmaceuticals Stock Caught a Cold This Week ↗

August 22, 2025

The few news items from and about the company weren't all that positive.

Via The Motley Fool

Topics Regulatory Compliance

Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial

August 12, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗

August 10, 2025

These companies are in the right place at the right time with the right products.

Via The Motley Fool

Topics Artificial Intelligence

Why Recursion Pharmaceuticals Stock Tanked on Tuesday ↗

August 05, 2025

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Via The Motley Fool

Recursion (RXRX) Q2 Revenue Jumps 33% ↗

August 05, 2025

Via The Motley Fool

Topics Artificial Intelligence

Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates ↗

August 05, 2025

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share,...

Via Benzinga

Recursion Pharmaceuticals-A (NASDAQ:RXRX) Reports Mixed Q2 2025 Earnings: Revenue Beat but EPS Miss ↗

August 05, 2025

Recursion Pharmaceuticals (RXRX) reported mixed Q2 2025 results, beating revenue estimates with $19.22M but missing EPS at -$0.41. Shares rose 5.5% pre-market amid clinical progress and Sanofi...

Via Chartmill

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 05, 2025

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7)

From Recursion Pharmaceuticals

Via GlobeNewswire

The Dawn of Hyper-Personalization: How Generative AI is Reshaping Our Digital World

August 04, 2025

The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

2 Beaten-Down Stocks With Incredible Upside Potential ↗

August 03, 2025

Getting in on the ground floor with these companies might lead to superior returns.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.